Pharma Business - February 22, 2021
Immunicum receives orphan drug designation
The European Medicines Agency Committee for Orphan Medicinal Products (COMP) has issued a positive opinion on the company’s application for orphan designation status for its Phase II clinical candidate, ilixadencel, for the treatment of Gastrointestinal Stromal Tumors (GIST). The COMP opinion was based on results from the Phase I/II clinical trial in GIST, a rare […]
In a new job - February 1, 2021
Immunicum recruits new Interim CFO
Immunicum has announced that effective immediately, Lotta Ferm will join the leadership team as interim Chief Financial Officer (CFO). Lotta Ferm succeeding Peter Hein, who will leave at the end of February. “As we rapidly advance our ongoing integration process, we welcome Lotta who has substantial experience with life science and biotech companies,” states Sven […]
Biotech Business - January 26, 2021
Immunicum receives Orphan Drug Designation
Immunicum has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for ilixadencel. Ilixadencel is a cell-based, off-the-shelf immune primer, for the treatment of Soft Tissue Sarcoma (STS). The designation recognizes results from the Phase I/II clinical trial in Gastrointestinal Stromal Tumors (GIST), a rare and difficult-to treat cancer indication belonging […]
Clinical Trials - December 21, 2020
Immunicum completes patient recruitment for Phase Ib trial
Immunicum has announced the completion of patient recruitment for the Phase Ib portion of the ongoing ILIAD (ILIxadencel in combination with checkpoint inhibitors in ADvanced cancer patients) trial. The primary objective of the Phase Ib study is to evaluate the safety and tolerability as well as define the dose regimen for Immunicum’s lead cell-based candidate, […]
Biotech Business - December 8, 2020
Immunicum receives Fast Track Designation
Immunicum has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for the company’s lead candidate, ilixadencel. Ilixadencel is a cell-based, off-the-shelf immune primer, for the treatment of the orphan indication, Gastrointestinal Stromal Tumors (GIST). The FDA’s decision is based on results from the Phase I/II clinical trial in GIST, a […]
Acquisition - November 19, 2020
Immunicum acquires all shares in DCprime
Immunicum has entered into an agreement with Van Herk Investments B.V. to acquire all of the shares in DCprime B.V., a Dutch clinical stage company developing cancer relapse vaccines aimed to reduce tumor recurrence. Merging the complementary allogeneic dendritic cell biology approaches of both companies will enable Immunicum to further build and strengthen its position […]
